Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSF1R | P07333 | 11/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661637 | 0.84 | HTT (0.45) | MAPT | |
| SCHEMBL5057753 | 0.82 | FDPS (0.39) | CSF1RMEN1KMT2A | |
| SCHEMBL1665583 | 0.81 | CSF1R (0.34) | CSF1R | |
| SCHEMBL5061848 | 0.80 | MET (0.36) | — | |
| SCHEMBL2333592 | 0.78 | — | — | |
| SCHEMBL662697 | 0.76 | ALDH1A1 (0.36) | MAPT | |
| SCHEMBL661395 | 0.76 | LMNA (0.47) | MEN1TP53KMT2AMAPT | |
| SCHEMBL30361114 | 0.76 | PRPS1 (0.39) | MEN1KMT2A | |
| SCHEMBL662340 | 0.76 | PRPS1 (0.39) | MEN1KMT2A | |
| SCHEMBL2955159 | 0.75 | POLB (0.32) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3610890-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2020-02-19 | — | — | EP | disclosed |
| EP-2968257-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968237-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | The Johns Hopkins University (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2968220-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | Agenebio, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2919788-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | The Johns Hopkins University (US) | 2015-09-23 | — | — | EP | disclosed |
| WO-2014144663-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144546-A1 | METHODS AND COMPOSITONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014144801-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | AGENEBIO INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014078568-A1 | METHODS AND COMPOSITIONS FOR TREATING SCHIZOPHRENIA | THE JOHNS HOPKINS UNIVERSITY (US) | 2014-05-22 | — | — | WO | disclosed |
| US-8586623-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2013-11-19 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8183241-B2 | 2-oxo-1-pyrrolidine derivatives | UCB PHARMA, S.A. (BE) | 2012-05-22 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| US-8178533-B2 | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses | UCB PHARMA, S.A. (BE) | 2012-05-15 | — | — | US | disclosed |
| WO-2011100373-A1 | METHODS AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION | THE JOHNS HOPKINS UNIVERSITY (US) | 2011-08-18 | — | — | WO | disclosed |
| EP-2308870-A2 | 2-oxo-1-pyrrolidine deriatives, processes for preparing them and their uses | UCB Pharma S.A. (BE) | 2011-04-13 | — | — | EP | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | UCB PHARMA, S.A. (BE) | 2009-12-17 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB, S.A. (BE) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312333-A1 | 2-Oxo-1-Pyrrolidine Derivatives, Processes for Preparing Them and Their Uses | CYP3A4, CYP1B1, CYP2D6 | CSF1R 4069/4885MEN1 3799/4885TP53 3291/4885 |
| US-20090156607-A1 | 2-OXO-1-PYRROLIDINE DERIVATIVES | OPRD1, PPOX, CYP2D6 | CSF1R 2829/4885MEN1 3884/4885TP53 2564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.